Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MupiroNasal versus Bactroban for nasal Staphylococcus aureus eradication
2018-002913-37Phase 4Completed
- Sponsor
- Antibiotic-Razgrad
- Start
- Dec 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mupirocin in Staphylococcus aureus nasal carriage and nasal carriage of methicillin-resistant Staphylococcus aureus (2 arms), sponsored by Antibiotic-Razgrad. Primary endpoint: Apparent eradication of nasal carriage of Staphylococcus aureus. Started Dec 2018; status: completed.
02
Drugs
mupirocin
03
Conditions
Staphylococcus aureus nasal carriagenasal carriage of methicillin-resistant Staphylococcus aureus
Beyond the preview
Go deeper on 2018-002913-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002913-37.